The Rip follows a group of detectives who come across millions of dollars in cash during an investigation. The reveal of the money throws into question who can be trusted and who is out for themselves ...

Note: This story contains spoilers from “His & Hers” Episode 6. For series star and executive producer, Tessa Thompson, the toughest part of crafting the “His & Hers” twisty ending was ensuring it ...

Netflix’s latest Korean blockbuster The Great Flood has surged to the top of the platform’s global charts for nonglobal films, but audiences are divided over its cryptic ending and philosophical twist ...

Staking is one of the most common ways crypto holders earn rewards simply by holding and committing their tokens to a blockchain network. Often described as “earning passive income in crypto,” staking ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Sci-Fi Shows Stranger Things season 5, Volume 2 review: “All set up for a finale that has so much to deliver” Sci-Fi Shows Stranger Things season 5 reviews, cast, plot, and everything else you need to ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

‘Predator: Badlands’ sees a Yautja Predator hero team up with a damaged synthetic (Elle Fanning), and is full of unexpected twists—here’s the ending, explained. Predator: Badlands makes a bold move, ...

Let's make this simple. You want to know if there are any mid- or post-credits scenes in Predator: Badlands; the answer is ‘not really.’ A title card flashes on ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...